Company intelligence / Profile preview

Inibio

Hwaseong-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Inibio is a South Korean biotechnology company specializing in the development and manufacture of botulinum toxin products for medical and aesthetic applications. The company's lead candidate, INI101, is a high-purity botulinum toxin type A designed to treat glabellar lines and other neuromuscular conditions. Inibio utilizes advanced fermentation and purification technologies to ensure product safety and competitive efficacy. The company operates a dedicated GMP-compliant manufacturing facility in Hwaseong to support its global commercialization strategy. Inibio is actively pursuing international market entries through clinical trials and strategic distribution partnerships.

Therapeutic areas: NeurologyDermatology
Modalities: BiologicProtein
Industry: Biotech

Drug pipeline

1 asset

INI101

Beyond the preview

Go deeper on Inibio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inibio.

Explore the full profile